January 2018 in “Dermatology Online Journal” Alopecia areata is hard to treat, but new targeted therapies show promise.
3 citations
,
July 2023 in “International journal of molecular sciences” Stress may contribute to hair loss in alopecia areata by affecting immune responses and cell death in hair follicles.
1 citations
,
November 2018 in “immuneACCESS” Expanded CD8+ T cells are linked to Alopecia Areata and may cause relapse after treatment.
April 2026 in “Journal of Inflammation Research” Alopecia areata and atopic dermatitis share immune system issues, and treatments like JAK inhibitors can help both.
January 2026 in “Experimental Dermatology” Skin-resident memory T cells may contribute to chronic alopecia areata and baricitinib could be a potential treatment.
April 2025 in “International Journal of Molecular Sciences” New treatments for hair loss show promise with advanced therapies and better targeting.
March 2025 in “Journal of Clinical Medicine” Iron chelators can effectively reduce hair loss and improve hair growth in autoimmune alopecia.
March 2024 in “Current issues in molecular biology” Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.
April 2026 in “Antibodies” The role of antibodies in alopecia is unclear, but JAK inhibitors show promise for treatment.
May 2025 in “JEADV Clinical Practice” Hair specialists vary in testing for alopecia areata, highlighting the need for standard guidelines.
August 2026 in “Journal of Clinical Medicine” Alopecia areata management in Poland faces challenges in treatment consistency and patient care, needing standardized practices and better public awareness.
11 citations
,
February 2022 in “JAAD case reports” Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.
October 2025 in “Dermatologica Sinica” A personalized treatment combining traditional and new therapies may improve hair loss outcomes in alopecia areata.
July 2025 in “Journal of Cosmetic Dermatology” Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
1 citations
,
June 2023 in “Genes” Hair loss from Alopecia Areata is caused by both genes and environment, with several treatments available but challenges in cost and relapse remain.
November 2023 in “Journal of Cosmetic Dermatology” Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
290 citations
,
August 2021 in “Clinical Reviews in Allergy & Immunology” JAK inhibitors show promise for treating alopecia areata, but more research is needed.
6 citations
,
November 2020 in “JAAD Case Reports” Tofacitinib may help treat both alopecia areata and inflammatory bowel disease.
5 citations
,
March 2019 in “Dermatologic Clinics” New treatments for hair loss show promise, but require more research on long-term effects and proper dosing.
4 citations
,
January 2025 in “Dermatologica Sinica” Experts recommend personalized treatment plans for alopecia areata, using corticosteroids and minoxidil for mild cases, and stronger medications for severe cases.
3 citations
,
October 2025 in “Biomedicines” New treatments for seborrheic dermatitis show promise for difficult cases.
2 citations
,
April 2023 in “Polymers” The study created 3D-printed pills that effectively release a hair loss treatment drug over 24 hours.
1 citations
,
December 2024 in “Indian Dermatology Online Journal” Biologics and small molecules can effectively treat inflammatory nail disorders, but personalized treatment plans are important.
November 2025 in “Biomedicines” Targeting pyroptosis may offer new treatments for alopecia areata, but more research is needed.
July 2025 in “Cell & Bioscience” Specific immune cells and pathways contribute to hair follicle inflammation and hair loss, suggesting potential treatments for lichen planopilaris.
New hair regrowth therapies show promise but need more research.
November 2024 in “Medicina” Recognizing scalp symptoms in PRP is crucial for proper diagnosis and treatment.
December 2023 in “Journal of Cosmetic Dermatology” Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
September 2023 in “Journal of The American Academy of Dermatology” Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
April 2025 in “Vestnik dermatologii i venerologii” JAK inhibitors like tofacitinib are effective and safer for severe alopecia areata than glucocorticosteroids.